Onasemnogene Abeparvovec Gene Therapy in Presymptomatic spinal muscular atrophy (SMA): SPR1NT study update in children with 3 Copies of SMN2

被引：2

作者：

Strauss, K. ^{[1
]}

Muntoni, F. ^{[2
]}

Farrar, M. ^{[3
]}

Saito, K. ^{[4
]}

Mendell, J. ^{[5
]}

Servais, L. ^{[6
]}

McMillan, H. ^{[7
]}

Swoboda, K. ^{[8
]}

Kwon, J. ^{[9
]}

Zaidman, C. ^{[10
]}

Chiriboga, C. ^{[11
]}

Iannaccone, S. ^{[12
]}

Krueger, J. ^{[13
]}

Parsons, J. ^{[14
]}

Shieh, P. ^{[15
]}

Kavanagh, S. ^{[16
]}

Chand, D. ^{[16
]}

Tauscher-Wisniewski, S. ^{[16
]}

Macek, T. ^{[16
]}

机构：

[1] Clin Special Children, Strasburg, PA USA

[2] UCL, London, England

[3] Sydney Childrens Hosp Network, Randwick, NSW, Australia

[4] Tokyo Womens Med Univ, Tokyo, Japan

[5] Nationwide Childrens Hosp, Columbus, OH USA

[6] MDUK Oxford Neuromuscular Ctr, Oxford, England

[7] Childrens Hosp Eastern Ontario, Ottawa, ON, Canada

[8] Massachusetts Gen Hosp, Boston, MA 02114 USA

[9] Univ WI, Sch Med & Publ Hlth, Madison, WI USA

[10] Washington Univ, Sch Med, St Louis, MO USA

[11] Columbia Univ, Med Ctr, New York, NY USA

[12] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[13] Helen DeVos Childrens Hosp, Grand Rapids, MI USA

[14] Univ Colorado, Sch Med, Aurora, CO USA

[15] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[16] Novartis Gene Therapies, Bannockburn, IL USA

来源：

NEUROMUSCULAR DISORDERS | 2021年 / 31卷

关键词：

D O I：

10.1016/j.nmd.2021.07.299

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EP.274

引用

页码：S133 / S133

页数：1

共 50 条

[21] Intravenous and intrathecal onasemnogene abeparvovec gene therapy in symptomatic and presymptomatic spinal muscular atrophy (SMA): long-term follow-up study
Darras, B.
Mercuri, E.
Strauss, K.
Day, J.
Chien, Y.
Masson, R.
Wigderson, M.
Alecu, I.
Ballarini, N.
Mehl, L.
Marra, J.
Connolly, A.
NEUROMUSCULAR DISORDERS, 2023, 33 : S87 - S87
[22] Risdiplam clinical trial outcomes in individuals with spinal muscular atrophy (SMA) and four SMN2 copies
Toy, F.
Bertini, E.
Chiriboga, C. A.
Mercuri, E.
Dickendesher, T.
Li, Y.
Martin, C.
Palfreeman, L.
Tam, S.
Yeung, W.
ANNALS OF NEUROLOGY, 2025, 96 : S126 - S127
[23] A tetracycline that corrects SMN2 splicing for potential therapy of spinal muscular atrophy (SMA)
Berniac, Joel
Hastings, Michelle L.
Liu, Ying-Hsiu
Dudley, Caroline
Larson, Kelley C.
Coovert, Daniel
Bowser, Todd
Higgins, Paul
Burghes, Arthur
Krainer, Adrian
NEUROLOGY, 2008, 70 (11) : A136 - A136
[24] Onasemnogene Abeparvovec Gene-Replacement Therapy (GRT) in Pre-symptomatic Spinal Muscular Atrophy (SMA)
Schultz, M.
Swoboda, K.
Farrar, M.
McMillan, H.
Parsons, J.
Kernbauer, E.
Farrow, M.
Ogrinc, F.
Kavanagh, S.
Feltner, D.
McGill, B.
Spector, S.
L'Italien, J.
Sproule, D.
Strauss, K.
ANNALS OF NEUROLOGY, 2019, 86 : S133 - S133
[25] Spinal presentations in children with spinal muscular atrophy type 1 following gene therapy treatment with onasemnogene abeparvovec - The SMA REACH UK network experience
Wolfe, Amy
Sheehan, Jennie
Schofield, Alex
Cranney, Helen
O'Reilly, Emer
Stimpson, Georgia
Andrews, Alice
Vanegas, Maria
Lucas, Jonathan
Scoto, Mariacristina
Gowda, Vasantha
Wraige, Elizabeth
Jungbluth, Heinz
NEUROMUSCULAR DISORDERS, 2024, 44
[26] Gene Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and Safety Considerations for Onasemnogene Abeparvovec (Zolgensma)
Ogbonmide, Tolu
Rathore, Rajni
Rangrej, Shahid B.
Hutchinson, Stedrea
Lewis, Marcia
Ojilere, Stephenie
Carvalho, Victoria
Kelly, Irenaissia
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (03)
[27] Onasemnogene abeparvovec gene-replacement therapy (GRT) in pre-symptomatic spinal muscular atrophy (SMA)
Schultz, M.
Swoboda, K.
Farrar, M.
McMillan, H.
Parsons, J.
Kernbauer, E.
Farrow, M.
Ogrinc, F.
Kavanagh, S.
Feltner, D.
McGill, B.
Spector, S.
L'Italien, J.
Sproule, D.
Strauss, K.
NEUROMUSCULAR DISORDERS, 2019, 29 : S183 - S183
[28] Onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy Type 1 (SMA1): Pivotal phase 3 study (STR1VE) update
Day, J.
Chiriboga, C.
Crawford, T.
Darras, B.
Finkel, R.
Connolly, A.
Iannaccone, S.
Kuntz, N.
Pena, L.
Schultz, M.
Shieh, P.
Smith, E.
Feltner, D.
Ogrinc, F.
Ouyang, H.
Macek, T.
Kernbauer, E.
Sproule, D.
Mendell, J.
NEUROMUSCULAR DISORDERS, 2019, 29 : S183 - S183
[29] Spinal Muscular Atrophy - Is Newborn Screening Too Late for Children with Two SMN2 Copies?
Schwartz, Oliver
Koelbel, Heike
Blaschek, Astrid
Glaeser, Dieter
Burggraf, Siegfried
Roeschinger, Wulf
Schara, Ulrike
Mueller-Felber, Wolfgang
Vill, Katharina
JOURNAL OF NEUROMUSCULAR DISEASES, 2022, 9 (03) : 389 - 396
[30] Onasemnogene Abeparvovec Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 1 (SMA1): Pivotal Phase 3 Study (STR1VE) Update
Day, J.
Chiriboga, C.
Crawford, T.
Darras, B.
Finkel, R.
Connolly, A.
Iannaccone, S.
Kuntz, N.
Pena, L.
Schultz, M.
Shieh, P.
Smith, E.
Feltner, D.
Ogrinc, F.
Shah, A.
Ouyang, H.
Macek, T.
Kernbauer, E.
L'Italien, J.
Sproule, D.
Kaspar, B.
Mendell, J.
ANNALS OF NEUROLOGY, 2019, 86 : S118 - S121

← 1 2 3 4 5 →